Ind-Swift Laboratories Limited has filed a regulatory disclosure under SEBI SAST regulations on December 18, 2025, regarding the completion of share transmission to the legal heirs of Late Mrs. Neera Mehta.

Share Transmission Details

The company transmitted 2,32,057 equity shares to the joint demat account of three legal heirs of Late Mrs. Neera Mehta. These shares were previously pending credit due to regulatory approvals required for the amalgamation of Ind-Swift Limited with Ind-Swift Laboratories Limited.

Regulatory Compliance

The transmission was completed under the exemption available under Regulation 10(1)(g) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation provides exemption for transmission of shares to legal heirs upon demise of a shareholder.

Rishav Mehta, acting as a Promoter and on behalf of the legal heirs, submitted the disclosure to both BSE Limited and National Stock Exchange of India Limited. The company confirmed that there is no change in the aggregate shareholding of the Promoters and Promoter Group following this transmission.

Shareholding Structure Post-Transaction

The post-transaction shareholding details reveal the distribution among the legal heirs:

The joint holding increased from 2,49,000 shares (0.31%) to 4,81,057 shares (0.59%) following the transmission of the remaining shares from Late Mrs. Neera Mehta's holding. The entire shareholding of Late Mrs. Neera Mehta has now been fully transmitted to the joint account of her legal heirs by way of transmission.

Filing Documentation

The disclosure was filed in compliance with Regulation 10(6) of the SEBI SAST Regulations, with all required details submitted to the stock exchanges. The filing includes comprehensive shareholding details and confirms that the transmission was completed relying upon the exemption available under the regulations for inter-se transfer of shares between promoters of the company.

Ind Swift Laboratories has achieved a significant regulatory milestone with its Derabassi formulations facility receiving EU-GMP compliance certification from Hungary's regulatory authority. This certification represents an important step forward for the pharmaceutical company's manufacturing operations and regulatory standing.

Regulatory Achievement Details

The EU-GMP (European Union Good Manufacturing Practice) compliance certificate validates that the Derabassi formulations facility meets the stringent quality and manufacturing standards required by European regulatory authorities. The certification was issued by Hungary's regulatory authority, which operates under the European Medicines Agency framework.

Significance of EU-GMP Compliance

EU-GMP compliance is a critical requirement for pharmaceutical manufacturers seeking to supply products to European Union markets. The certification ensures that manufacturing processes, quality control systems, and facility standards meet European regulatory requirements. This achievement demonstrates Ind-Swift Laboratories' commitment to maintaining international quality standards in its manufacturing operations.

Manufacturing Facility Enhancement

The Derabassi formulations facility's EU-GMP certification enhances the company's manufacturing credentials and regulatory portfolio. This certification potentially enables the facility to manufacture pharmaceutical products that comply with European Union standards, which could facilitate market access and business opportunities within EU territories.

The achievement reflects the company's focus on maintaining high-quality manufacturing standards and regulatory compliance across its pharmaceutical operations. Such certifications are essential for pharmaceutical companies operating in the global marketplace, where regulatory compliance is paramount for market access and business growth.